The plan includes a list of suggested factors for the HHS to consider, including an assessment of a project's risks and benefits, and a determination of whether the investigator and institution are capable of conducting the work safely. It also says that an experiment should proceed only if there is no safer alternative method of achieving the same results.
At the end of the assessment process, the HHS can recommend that the work go ahead, ask the researchers to modify their plan or suggest that the NIH refuse funding. The NIH will also judge the proposal's scientific merit before deciding whether to award grant funding.
Scientists have long debated the merits of gain-of-function research and the new decision could reopen that discussion.
Yoshihiro Kawaoka, a virologist at the University of Wisconsin-Madison, whose work was affected by the moratorium, says the new framework is "an important accomplishment". Kawaoka, who studies how molecular changes in the avian flu virus could make it easier for birds to pass the infection to humans, now plans to apply for federal funding to experiment with live versions of the virus.
But Marc Lipsitch, an epidemiologist at the Harvard T.H. Chan School of Public Health in Boston, Massachusetts, says that gain-offunction studies "have done almost nothing to improve our preparedness for pandemics -yet they risked creating an accidental pandemic".
Lipsitch argues that such experiments should not happen at all. But if the government is going to fund them, he says, it is good that there will be an extra level of review. ■ in terms of impact on research, Open Phil will soon rival better-known philanthropy vehicles, such as the Chan Zuckerberg Initiative in Palo Alto, California, which among other efforts awarded $50 million in life-sciences grants in 2017 to create a biohub in the San Francisco Bay Area.
Open Phil, based in San Francisco, acknowledges the high odds of failure of the basic research it funds and, for a private funder, publishes brutally honest assessments of its projects. These range from developing lab-made meat alternatives to work on a controversial genetic-engineering technology called gene drive. For its latest funding round, Open Phil asked scientists whose grant applications had been rejected by an NIH competition for risky research to dust off their proposals. Some 120 researchers resubmitted their requests, and it awarded $10.8 million in total to four teams.
"My hope is Open Philanthropy can make the world safe for serendipity again, " says Ed Boyden, a neuroscientist at the Massachusetts Institute of Technology in Cambridge, who won $3 million from the project in 2016. He is working to develop a technology that swells tissue to make it easier to examine under a microscope.
TAKING A PUNT
Gregory Timp, a biophysicist at the University of Notre Dame in South Bend, Indiana, who has won $2 million from Open Phil to develop a technology to sequence proteins, says that the evaluation process involved rebutting each of the NIH's critiques of his proposal, as well as several rounds of interviews with scientist advisers. "They have scientific rigour couched in California casual. Everything is informal, but they ask these piercing questions, " he says.
Katherina Rosqueta, founding executive director of the Center for High Impact Philanthropy at the University of Pennsylvania in Philadelphia, says that the project's efforts to share its extensive research and justify its giving makes it stand out among private funders. "They have a highly analytical view. They have an appetite and skill in conducting research and sourcing information, and they're willing to do that in a public and transparent way. "
Many philanthropists shy away from basic science because the pay-offs tend to be long term and the risks high, 
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